Advertisement

Topics

NICE recommends routine NHS funding for new breast cancer drugs

07:47 EST 16 Nov 2017 | British Medical Journal

The new breast cancer drugs palbociclib (Ibrance, Pfizer) and ribociclib (Kisqali, Novartis) should be routinely funded on the NHS, draft guidance from the National Institute for Health and Care...

Original Article: NICE recommends routine NHS funding for new breast cancer drugs

NEXT ARTICLE

More From BioPortfolio on "NICE recommends routine NHS funding for new breast cancer drugs"

Quick Search
Advertisement
 

Relevant Topics

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...